Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BNTX – BioNTech SE

Float Short %

2.55

Margin Of Safety %

Put/Call OI Ratio

0.83

EPS Next Q Diff

0.82

EPS Last/This Y

-0.87

EPS This/Next Y

0.33

Price

110.95

Target Price

141.33

Analyst Recom

1.58

Performance Q

11.92

Relative Volume

0.48

Beta

1.4

Ticker: BNTX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25BNTX115.290.860.5340855
2025-07-28BNTX112.870.851.1541984
2025-07-29BNTX111.570.860.6442332
2025-07-30BNTX110.090.850.6642865
2025-07-31BNTX107.540.851.1842884
2025-08-01BNTX107.40.851.9843016
2025-08-04BNTX110.590.860.6943329
2025-08-05BNTX111.040.860.0943570
2025-08-06BNTX111.380.890.7942537
2025-08-07BNTX111.30.890.6742491
2025-08-08BNTX111.740.890.0842523
2025-08-11BNTX109.290.890.8242592
2025-08-12BNTX111.110.900.2842818
2025-08-13BNTX112.730.880.1443767
2025-08-14BNTX112.580.771.9548347
2025-08-15BNTX113.520.800.6351262
2025-08-18BNTX112.580.840.3347178
2025-08-19BNTX111.460.840.7447468
2025-08-20BNTX111.280.840.0948110
2025-08-21BNTX110.210.840.0448273
2025-08-22BNTX110.90.830.1448656
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25BNTX115.3142.7-1388.2-3.84
2025-07-28BNTX112.8543.3-1243.2-3.60
2025-07-29BNTX111.4843.3-1295.5-3.60
2025-07-30BNTX110.0558.2-1242.4-3.30
2025-07-31BNTX107.5058.2-1166.6-3.30
2025-08-01BNTX107.3458.2-1282.5-3.27
2025-08-04BNTX110.0358.2-1394.0-3.27
2025-08-05BNTX111.0758.2-1304.4-3.27
2025-08-06BNTX111.33-122.6-1797.4-4.04
2025-08-07BNTX111.35-122.6-1784.7-4.04
2025-08-08BNTX111.66-122.6-1820.6-4.04
2025-08-11BNTX109.31-122.6-1691.7-4.04
2025-08-12BNTX111.01-122.6-1892.4-4.04
2025-08-13BNTX112.78-122.6-1888.3-4.04
2025-08-14BNTX112.62-123.1-1079.9-3.82
2025-08-15BNTX113.50-123.1-1130.4-4.18
2025-08-18BNTX112.55-126.8-1060.3-4.18
2025-08-19BNTX111.40-126.8-1064.7-4.19
2025-08-20BNTX111.27-126.8-1092.3-4.19
2025-08-21BNTX110.69-126.8-1071.0-4.12
2025-08-22BNTX110.95-126.8-1099.5-4.12
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25BNTX0.001.792.55
2025-07-28BNTX0.001.302.55
2025-07-29BNTX0.001.302.55
2025-07-30BNTX0.001.302.55
2025-07-31BNTX0.001.302.55
2025-08-01BNTX0.001.302.55
2025-08-04BNTX0.001.822.55
2025-08-05BNTX0.001.822.55
2025-08-06BNTX0.001.822.55
2025-08-07BNTX0.001.822.55
2025-08-08BNTX0.001.822.55
2025-08-11BNTX0.002.102.55
2025-08-12BNTX0.002.102.56
2025-08-13BNTX0.002.102.56
2025-08-14BNTX0.002.102.56
2025-08-15BNTX0.002.102.56
2025-08-18BNTX0.002.172.55
2025-08-19BNTX0.002.172.55
2025-08-20BNTX0.002.172.55
2025-08-21BNTX0.002.172.55
2025-08-22BNTX0.002.172.55
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.82

Avg. EPS Est. Current Quarter

-0.22

Avg. EPS Est. Next Quarter

-1

Insider Transactions

Institutional Transactions

2.17

Beta

1.4

Average Sales Estimate Current Quarter

1015

Average Sales Estimate Next Quarter

944

Fair Value

Quality Score

58

Growth Score

37

Sentiment Score

10

Actual DrawDown %

76.1

Max Drawdown 5-Year %

-82.2

Target Price

141.33

P/E

Forward P/E

PEG

P/S

8.53

P/B

1.23

P/Free Cash Flow

EPS

-1.6

Average EPS Est. Cur. Y​

-4.12

EPS Next Y. (Est.)

-3.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-12.21

Relative Volume

0.48

Return on Equity vs Sector %

-26.6

Return on Equity vs Industry %

-13.6

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.29

EBIT Estimation

-1099.5
BioNTech SE
Sector: Healthcare
Industry: Biotechnology
Employees: 6772
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
stock quote shares BNTX – BioNTech SE Stock Price stock today
news today BNTX – BioNTech SE stock forecast ,stock prediction 2023 2024 2025
marketwatch BNTX – BioNTech SE yahoo finance google finance
stock history BNTX – BioNTech SE invest stock market
stock prices BNTX premarket after hours
ticker BNTX fair value insiders trading